April 29 (Reuters) – Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment in patients who received at least one prior line of treatment.
Here are further details on the trial:
• Elrexfio has the U.S. Food and Drug Administration’s accelerated approval for treating patients with multiple myeloma who have received at least four prior lines of treatment.
• Multiple myeloma is a cancer of the plasma cells, a type of white blood cell in the bone marrow that helps fight infection.
• Pfizer said the drug showed clinically meaningful improvement in progression free survival, or living without the disease worsening, when compared to standard of care treatment.
• The trial remains ongoing to assess overall survival, a key secondary goal, as the data was not yet available at the time of this interim analysis, the company said.
• The company said the trial data will be discussed with global health authorities.
• Pfizer recorded Elrexfio sales of $304 million in 2025.
• Multiple myeloma accounts for roughly 1% to 2% of all cancers and 10% of blood cancers. Over 32,000 new cases are diagnosed annually in the US.
(Reporting by Christy Santhosh in Bengaluru)
